Literature DB >> 24514021

Hypertension: Strengths and limitations of the JNC 8 hypertension guidelines.

Giuseppe Mancia1.   

Abstract

The Eighth Joint National Committee (JNC 8) guidelines on hypertension have generated great interest among physicians. These guidelines differ from those published in 2003 (the JNC 7) - in the document format, blood-pressure cut-off values, and recommendations for antihypertensive drug use. The JNC 8 have some limitations that could affect clinical practice.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24514021     DOI： 10.1038/nrcardio.2014.12

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  10 in total

1.  Hypertension management in adults with diabetes.

Authors:  Carlos Arauz-Pacheco; Marian A Parrott; Phillip Raskin
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

2.  US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008.

Authors:  Brent M Egan; Yumin Zhao; R Neal Axon
Journal:  JAMA       Date:  2010-05-26       Impact factor: 56.272

3.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; José Luis Zamorano; Serap Erdine; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Lars H Lindholm; Margus Viigimaa; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Bernard Waeber; Bryan Williams
Journal:  J Hypertens       Date:  2007-06       Impact factor: 4.844

4.  Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement.

Authors:  Giuseppe Mancia; Guido Grassi
Journal:  Hypertension       Date:  2014-01       Impact factor: 10.190

5.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

6.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

7.  When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal.

Authors:  Alberto Zanchetti; Guido Grassi; Giuseppe Mancia
Journal:  J Hypertens       Date:  2009-05       Impact factor: 4.844

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redón; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad
Journal:  J Hypertens       Date:  2013-07       Impact factor: 4.844

10.  Individualization of antihypertensive drug treatment.

Authors:  Giuseppe Mancia; Guido Grassi
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112
  10 in total
  3 in total

1.  Assessment of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Retinol-Binding Protein 4 (RBP4) in Type 2 Diabetic Patients with Nephropathy.

Authors:  Mohamed H Mahfouz; Adel M Assiri; Mohammed H Mukhtar
Journal:  Biomark Insights       Date:  2016-02-16

2.  Metabolomics Based Profiling of Dexamethasone Side Effects in Rats.

Authors:  Abeer K Malkawi; Karem H Alzoubi; Minnie Jacob; Goran Matic; Asmaa Ali; Achraf Al Faraj; Falah Almuhanna; Majed Dasouki; Anas M Abdel Rahman
Journal:  Front Pharmacol       Date:  2018-02-16       Impact factor: 5.810

3.  Comparison of Two Different Semiquantitative Urinary Dipstick Tests with Albumin-to-Creatinine Ratio for Screening and Classification of Albuminuria According to KDIGO. A Diagnostic Test Study.

Authors:  Nikolai C Hodel; Ali Hamad; Klaus Reither; Irene Mndala Kasella; Salim Abdulla; Andreas Schoetzau; Christoph F R Hatz; Michael Mayr
Journal:  Diagnostics (Basel)       Date:  2021-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.